文献速递瓣膜外科

欧洲NeoChord植入行经心尖非停跳二尖瓣修复的早期经验

An early European experience with transapical off-pump mitral valve repair with NeoChord implantation.
PubMed 文献 · Eur J Cardiothorac Surg · 2018-01-01

该研究基于NeoChord独立国际注册研究,纳入2013年2月至2016年7月213例因瓣叶脱垂/连枷导致重度二尖瓣反流的患者,行经心尖非停跳NeoChord修复。手术成功206例(96.7%),1年总生存98±1%,复合终点总体84±2.5%,Type A、B、C组分别为94±2.6%、82.6±3.8%、63.6±8.4%(P<0.0001)。作者认为该手术安全、有效、可重复,但需特定解剖选择标准以获得稳定结果。

要点

  • 经心尖非停跳NeoChord修复手术成功206/213例(96.7%)。
  • 1年复合终点总体84±2.5%,Type A 94±2.6%、Type B 82.6±3.8%、Type C 63.6±8.4%(P<0.0001)。
  • 作者认为需特定解剖选择标准以获得稳定结果。

核心结论

  • NeoChord手术安全、有效且可重复,临床与超声心动图疗效维持至1年,不同解剖分组间差异显著,需特定解剖选择标准以获得稳定结果。

研究设计与样本

  • 前瞻性国际注册研究(NeoChord独立国际注册研究),纳入2013年2月至2016年7月213例因瓣叶脱垂/连枷导致重度二尖瓣反流的连续患者,均完成术后1年超声心动图评估。

主要发现

  • 中位年龄68岁(四分位距56-77),中位EuroSCORE II为1.05%(四分位距0.67-1.76)。
  • Type A、B、C组患者分别为82例(38.5%)、98例(46%)、33例(15.5%)。
  • 手术成功206例(96.7%),1年总生存98±1%。
  • 1年复合终点总体84±2.5%,Type A组94±2.6%、Type B组82.6±3.8%、Type C组63.6±8.4%(P<0.0001)。

关键数值与推荐

  • 解剖分型:Type A为孤立中央后叶病变;Type B为后叶多节段病变;Type C为前叶、双叶、旁交界区病变伴或不伴瓣叶/瓣环钙化。
  • 主要终点为手术成功、免于死亡、卒中、再干预、重度二尖瓣反流复发、再住院及1年随访时纽约心脏协会功能分级至少改善1级的复合终点。

临床怎么用

  • 作者认为NeoChord手术安全、有效且可重复,但需特定解剖选择标准以获得稳定结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Transapical off-pump NeoChord repair is a novel minimally invasive surgical procedure to treat degenerative mitral valve regurgitation. The aim was to evaluate 1-year clinical results of the NeoChord procedure in a consecutive cohort of patients. METHODS: Between February 2013 and July 2016, 213 patients were enrolled in the NeoChord Independent International Registry. All patients presented severe mitral regurgitation due to flail/prolapse of 1 or both leaflets, and they all completed postoperative echocardiographic assessment up to 1 year. We identified the primary end point as composed of procedural success, freedom from mortality, stroke, reintervention, recurrence of severe mitral regurgitation, rehospitalization and decrease of at least 1 New York Heart Association functional class at 1-year follow-up. We also compared outcomes according to the anatomical classification (Type A: isolated central posterior leaflet disease; Type B: posterior multisegment disease; Type C: anterior, bileaflet, paracommissural disease with/without leaflet/annular calcifications). RESULTS: The median age was 68 years (interquartile range 56-77), and the median EuroSCORE II was 1.05% (interquartile range 0.67-1.76). The number of Type A, B and C patients was 82 (38.5%), 98 (46%) and 33 (15.5%), respectively. Procedural success was achieved in 206 (96.7%) patients. At 1-year follow-up, overall survival was 98 ± 1%. Composite end point was achieved in 84 ± 2.5% for the overall population and 94 ± 2.6%, 82.6 ± 3.8% and 63.6 ± 8.4% in Type A, Type B and Type C patients, respectively (P < 0.0001). CONCLUSIONS: These results demonstrate that the NeoChord procedure is safe, effective and reproducible. Clinical and echocardiographic efficacy is maintained up to 1 year with significant differences among the anatomical groups. Specific anatomical selection criteria are necessary to achieve stable results.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Colli A, Manzan E, Aidietis A, et al. An early European experience with transapical off-pump mitral valve repair with NeoChord implantation. Eur J Cardiothorac Surg. 2018. PMID: 29514183. doi:10.1093/ejcts/ezy064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。